JP2019528307A5 - - Google Patents

Download PDF

Info

Publication number
JP2019528307A5
JP2019528307A5 JP2019511664A JP2019511664A JP2019528307A5 JP 2019528307 A5 JP2019528307 A5 JP 2019528307A5 JP 2019511664 A JP2019511664 A JP 2019511664A JP 2019511664 A JP2019511664 A JP 2019511664A JP 2019528307 A5 JP2019528307 A5 JP 2019528307A5
Authority
JP
Japan
Prior art keywords
phenyl
diamine
isopropylsulfonyl
pyrimidine
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019511664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528307A (ja
JP7094566B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/048845 external-priority patent/WO2018044767A2/en
Publication of JP2019528307A publication Critical patent/JP2019528307A/ja
Publication of JP2019528307A5 publication Critical patent/JP2019528307A5/ja
Priority to JP2022096630A priority Critical patent/JP2022120151A/ja
Application granted granted Critical
Publication of JP7094566B2 publication Critical patent/JP7094566B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019511664A 2016-08-29 2017-08-28 Alk阻害剤としてのアミノピリミジン類 Active JP7094566B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022096630A JP2022120151A (ja) 2016-08-29 2022-06-15 Alk阻害剤としてのアミノピリミジン類

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380818P 2016-08-29 2016-08-29
US62/380,818 2016-08-29
PCT/US2017/048845 WO2018044767A2 (en) 2016-08-29 2017-08-28 Aminopyrimidines as alk inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022096630A Division JP2022120151A (ja) 2016-08-29 2022-06-15 Alk阻害剤としてのアミノピリミジン類

Publications (3)

Publication Number Publication Date
JP2019528307A JP2019528307A (ja) 2019-10-10
JP2019528307A5 true JP2019528307A5 (OSRAM) 2020-10-01
JP7094566B2 JP7094566B2 (ja) 2022-07-04

Family

ID=59846649

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019511664A Active JP7094566B2 (ja) 2016-08-29 2017-08-28 Alk阻害剤としてのアミノピリミジン類
JP2022096630A Pending JP2022120151A (ja) 2016-08-29 2022-06-15 Alk阻害剤としてのアミノピリミジン類

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022096630A Pending JP2022120151A (ja) 2016-08-29 2022-06-15 Alk阻害剤としてのアミノピリミジン類

Country Status (12)

Country Link
US (2) US10709705B2 (OSRAM)
EP (2) EP3504203B1 (OSRAM)
JP (2) JP7094566B2 (OSRAM)
KR (1) KR102530871B1 (OSRAM)
CN (2) CN109715620B (OSRAM)
AU (2) AU2017319135B2 (OSRAM)
CA (1) CA3033223A1 (OSRAM)
IL (1) IL264638B (OSRAM)
MX (2) MX389265B (OSRAM)
NZ (1) NZ751713A (OSRAM)
SG (2) SG10201914030UA (OSRAM)
WO (1) WO2018044767A2 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020024825A1 (en) * 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Method for treating cancer by combination of fak/alk/ros1 inhibitor and egfr inhibitor
CN111171033B (zh) * 2018-11-09 2021-11-02 天津大学 一种嘧啶衍生物及其合成方法和应用
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110143947B (zh) * 2019-05-29 2021-10-15 华东师范大学 一种色瑞替尼类似物的制备方法
WO2020259553A1 (en) * 2019-06-25 2020-12-30 Ascentage Pharma (Suzhou) Co., Ltd. Combination of fak inhibitor and btk inhibitor for treating a disease
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN116261455B (zh) * 2020-09-25 2024-11-01 苏州亚盛药业有限公司 一种药物组合物及其在治疗癌症中的用途
WO2022222932A1 (en) * 2021-04-19 2022-10-27 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical combination and use thereof
CA3238857A1 (en) * 2021-12-09 2023-06-15 Oncobix Co., Ltd. Novel heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same
CN116332919B (zh) * 2022-03-30 2025-08-26 苏州亚盛药业有限公司 一种alk抑制剂化合物及其中间体的制备方法
WO2024153228A1 (zh) 2023-01-20 2024-07-25 苏州亚盛药业有限公司 Alk抑制剂或其盐、溶剂合物的结晶形式及其制备方法和应用
CN118680946A (zh) * 2023-03-22 2024-09-24 苏州亚盛药业有限公司 药物组合及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP4607879B2 (ja) 2003-08-15 2011-01-05 ノバルティス アーゲー 新生物疾患、炎症および免疫障害の処置に有用な2,4−ピリミジンジアミン
CA2538413A1 (en) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
WO2005097791A1 (en) * 2004-04-07 2005-10-20 Novartis Ag Inhibitors of iap
RS53588B1 (sr) 2006-12-08 2015-02-27 Irm Llc Jedinjenja i kompozicije kao inhibitori protein kinaza
CA2720946C (en) 2008-04-07 2013-05-28 Irm Llc Compounds and compositions as protein kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
CA2810900A1 (en) 2010-10-14 2012-04-19 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in egfr-driven cancers
ME02200B (me) * 2011-02-02 2016-02-20 Novartis Ag Postupci za korisćenje alk inhibitora
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물

Similar Documents

Publication Publication Date Title
JP2019528307A5 (OSRAM)
EP2488178B1 (en) Combinations of a pi3k inhibitor and a mek inhibitor
JP2019511528A5 (OSRAM)
JP2015533177A5 (OSRAM)
JP2017008088A5 (OSRAM)
JP2020007311A5 (OSRAM)
CN103402519B (zh) 肿瘤治疗剂
JP2019526615A5 (OSRAM)
JP2017528487A5 (OSRAM)
JP2018526376A5 (OSRAM)
JP2016538313A5 (OSRAM)
JPWO2022173678A5 (OSRAM)
RU2016141934A (ru) Ингибиторы циклин-зависимой киназы 7 (cdk7)
JP2015508103A5 (OSRAM)
JP2011001339A5 (OSRAM)
JP2016522232A5 (OSRAM)
JP2019501195A5 (ja) 腫瘍を処置するための抗egfr組み合わせ
JP2015514808A5 (OSRAM)
JP2006507271A5 (OSRAM)
JP2015514806A5 (OSRAM)
RU2013147744A (ru) Дозированная лекарственная форма для перорального применения
JP2016525076A5 (OSRAM)
JP2015504067A5 (OSRAM)
RU2017102319A (ru) Прерывистое введение ингибитора mdm2
JP2011515397A5 (OSRAM)